Efficacy of Antiviral Therapy in Pregnancy in Preventing Vertical Transmission of HBV in Mothers With a High Viral Load
Efficacy of Antiviral Therapy in Pregnancy in Preventing Vertical Transmission of HBV in Mothers With a High Viral Load
Mother-to-child transmission (MTCT) is the most common route of hepatitis B virus (HBV)
 infection. After given standard immunoprophylaxis, MTCT still occurred in some infants born
 to a HBsAg positive mothers with high HBV DNA load. The main purpose of this study is
 evaluating the efficacy of methods used in blocking MTCT of HBV in infants born to a HBsAg
 positive mothers with high serum HBV DNA loads.
This study contain 600 patients and compose groups as follow: (ⅰ) infants born to a HBsAg
 positive mothers with high HBV DNA load before delivery receive standard immunoprophylaxis(
 injection of HBIG 200IU at birth plus HBV vaccine at 0,1 and 6month); (ⅱ) infants born to a
 HBsAg positive mother with high HBV DNA load before delivery, and based on standard
 immunoprophylaxis receive addition injection of HBIG 200IU at 1 month after birth; (ⅲ)
 infants born to a HBsAg positive and high HBV DNA load mothers but treated with antiviral
 therapy in late pregnancy, receive standard immunoprophylaxis; (ⅳ) infants born to a HBsAg
 positive mothers treated with antiviral therapy during entire pregnancy for hepatitis receive
 standard immunoprophylaxis; (ⅴ) infants born to a HBsAg positive mother with serum HBV DNA
 negative receive standard immunoprophylaxis.
Inclusion Criteria:

 -  infants born to HBsAg positive mother HBsAg positive mother

 Exclusion Criteria:

 -  mothers coinfected HIV or HCV